1
40
1
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.1002/cncr.28306" target="_blank" rel="noreferrer noopener">http://doi.org/10.1002/cncr.28306</a>
Rights
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
Pages
3821-3829
Issue
21
Volume
119
Search for Full-text
Locate full-text within NEOMED Library's e-journal collections
<p>Users with a NEOMED Library login can search for full-text journal articles at the following url: <a href="https://libraryguides.neomed.edu/home">https://libraryguides.neomed.edu/home</a></p>
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Clinical Characteristics and Outcomes With Specific BRAF and NRAS Mutations in Patients With Metastatic Melanoma
Publisher
An entity responsible for making the resource available
Cancer
Date
A point or period of time associated with an event in the lifecycle of the resource
2013
2013-11
Subject
The topic of the resource
cancer; survival; Oncology; multicenter; BRAF; clinical features; dabrafenib; dose-escalation trial; improved; mek inhibitor trametinib; melanoma; NRAS; open-label; prognostic factor; selumetinib; stage IV; v600e; vemurafenib
Creator
An entity primarily responsible for making the resource
Bucheit A D; Syklawer E; Jakob J A; Bassett R L; Curry J L; Gershenwald J E; Kim K B; Hwu P; Lazar A J; Davies M A
Description
An account of the resource
BACKGROUNDHotspot mutations in BRAF and NRAS are the most common somatic events in patients with melanoma. These mutations occur at highly conserved residues, but include several different substitutions. To determine whether specific mutations are clinically important to differentiate, tumor characteristics and clinical outcomes were compared among patients with advanced melanoma with 1) BRAF V600E versus V600K mutations and 2) NRAS exon 1 versus exon 2 mutations. METHODSRetrospective clinical and pathologic data were collected for patients with advanced melanoma with BRAF or NRAS mutations. The demographics, tumor characteristics, and clinical outcomes of the patients were compared to identify significant mutation-specific associations. RESULTSAmong 302 patients with activating BRAF mutations, 76% had BRAF V600E and 24% had V600K substitutions. Compared with V600E, the presence of a V600K mutation was significantly associated with older age (median, 60.0 years vs 44.7 years; P<.001), male sex (80% vs 59%; P=.001), head/neck primary tumor location (30% vs 15%; P=.0026), shorter interval to stage IV disease (0.98 years vs 2.8 years; P=.015), and a shorter overall survival from the time of diagnosis of stage IV disease (median, 2.44 years vs 1.25 years; hazards ratio, 1.68 [P=.014]). Comparison of 136 patients with NRAS exon 1 (18%) and exon 2 (82%) mutations found an association with primary tumor histology (P=.0096) only. CONCLUSIONSThe presence of different substitutions at BRAF V600 correlates with patient demographics, tumor characteristics, and prognosis. These findings demonstrate the presence of mutation-specific clinical differences between different BRAF genotypes in patients with melanoma, and support the incorporation of this information in patient evaluation and clinical trial design. Cancer 2013;119:3821-3829. (c) 2013 American Cancer Society.
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1002/cncr.28306" target="_blank" rel="noreferrer noopener">10.1002/cncr.28306</a>
Format
The file format, physical medium, or dimensions of the resource
Journal Article or Conference Abstract Publication
2013
Bassett R L
BRAF
Bucheit A D
Cancer
clinical features
Curry J L
dabrafenib
Davies M A
dose-escalation trial
Gershenwald J E
Hwu P
improved
Jakob J A
Journal Article or Conference Abstract Publication
Kim K B
Lazar A J
mek inhibitor trametinib
Melanoma
multicenter
NRAS
oncology
open-label
prognostic factor
selumetinib
stage IV
Survival
Syklawer E
v600e
vemurafenib